Ken Griffin Collegium Pharmaceutical, Inc Put Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$31.4 - $39.07 $47,100 - $58,605	1,500 Added 18.07%	9,800 $378,000
Q2 2024 Aug 14, 2024	BUY	$31.36 - $39.99 $100,352 - $127,968	3,200 Added 62.75%	8,300 $267,000
Q1 2024 May 15, 2024	BUY	$31.23 - $40.91 $128,043 - $167,731	4,100 Added 410.0%	5,100 $197,000
Q4 2023 Feb 14, 2024	BUY	$21.16 - $30.8 $21,160 - $30,800	1,000 New	1,000 $30,000
Q2 2023 Aug 14, 2023	SELL	$21.06 - $24.0 $33,696 - $38,400	-1,600 Reduced 94.12%	100 $2,000
Q1 2023 May 15, 2023	BUY	$23.0 - $29.88 $6,900 - $8,964	300 Added 21.43%	1,700 $40,000
Q4 2022 Feb 14, 2023	BUY	$16.14 - $23.55 $22,596 - $32,970	1,400 New	1,400 $32,000

255

36.9M

100K

21.1K

Ticker COLL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 34,126,200
Market Cap $992M
Description
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.